Australia markets close in 5 hours 36 minutes

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.52+0.54 (+10.84%)
At close: 04:00PM EST
5.52 0.00 (0.00%)
After hours: 06:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.98
Open5.10
Bid4.36 x 3100
Ask6.00 x 800
Day's range5.04 - 5.60
52-week range1.37 - 16.80
Volume149,381
Avg. volume34,400
Market cap18.454M
Beta (5Y monthly)0.26
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

    Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTISOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its abstract entitled “Real-World Healthcare Resource Utilization of Patients Treated with Metoclo

  • GlobeNewswire

    USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

    SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.” This patent expires in 2038 and covers the methods for treating moderate-to-

  • GlobeNewswire

    Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

    SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled “Nasal Formulations of Metoclopramide” will expire in December 2029. This